Requests that the FDA recognize Auryxia's regulatory exclusivity, require ANDAs for generic versions of Auryxia to be supported with in vivo bioequivalence (BE) data to address Auryxia's systemic effects, and data showing qualitative and quantitative sameness with regards to the major ions and counterions found in Auryxia's active moiety